Skip to main content
. 2022 May 23;40(31):3593–3602. doi: 10.1200/JCO.21.02278

FIG A1.

FIG A1.

PFS by blinded independent central review assessment in patients with baseline brain metastases who received lorlatinib treatment by prior brain radiotherapy (intent-to-treat population). NR, not reported; PFS, progression-free survival; RT, radiotherapy.